Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter McLaughlin

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
British Journal of Haematology|July 5, 2007
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang, Luis Fayad, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Yasuhiro Oki, Barbara Pro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancersHagop M Kantarjian, Varsha Gandhi, Peter Kozuch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantationMaricer P Escalón, Richard E Champlin, Rima M Saliba, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2010
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based reviewDenise M Oliansky, Leo I Gordon, Jerry King, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypesAnas Younes, Jorge Romaguera, Michelle Fanale, et al.
British Journal of Haematology|August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study databasePhilippe Solal-Céligny, Monica Bellei, Luigi Marcheselli, et al.
British Journal of Haematology|March 2, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphomaTamer Khashab, Fredrick Hagemeister, Jorge E Romaguera, et al.
Blood|October 24, 2002
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaApostolia M Tsimberidou, Peter McLaughlin, Anas Younes, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
British Journal of Haematology|July 5, 2007
Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphomaNam H Dang, Luis Fayad, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Yasuhiro Oki, Barbara Pro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancersHagop M Kantarjian, Varsha Gandhi, Peter Kozuch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2004
Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantationMaricer P Escalón, Richard E Champlin, Rima M Saliba, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2010
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based reviewDenise M Oliansky, Leo I Gordon, Jerry King, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypesAnas Younes, Jorge Romaguera, Michelle Fanale, et al.
British Journal of Haematology|August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study databasePhilippe Solal-Céligny, Monica Bellei, Luigi Marcheselli, et al.
British Journal of Haematology|March 2, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphomaTamer Khashab, Fredrick Hagemeister, Jorge E Romaguera, et al.
Blood|October 24, 2002
Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent lymphomaApostolia M Tsimberidou, Peter McLaughlin, Anas Younes, et al.
Pageof 12